Isomorphic Labs readies preclinical AI drug engine for cancer treatments

Isomorphic Labs, a Google DeepMind spinoff, is developing AI models aimed at revolutionizing drug discovery by predicting molecular interactions to design treatments for cancer and other complex diseases. Led by Max Jaderberg, the company is moving toward preclinical trials using a proprietary drug design engine, though experts urge caution given the immense regulatory and biological hurdles of drug development. Open article →